Judge Quashes Teva Bid To Introduce Generic Evista

Law360, New York (September 24, 2009, 3:01 PM EDT) -- A federal judge has permanently blocked Teva Pharmaceuticals USA Inc. from launching a copy of Eli Lilly & Co.'s blockbuster osteoporosis drug Evista, rejecting Teva's argument that four Lilly patents are invalid.

Judge Sarah Evans Baker of the U.S. District Court for the Southern District of Indiana ruled Wednesday following a bench trial that four of the seven patents asserted by Lilly were valid, and would be infringed by Teva's proposed drug.

Those patents cover the oral administration of raloxifene hydrochloride to combat bone loss in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.